Logo

Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia

Share this

Janssen's Invega Hafyera (paliperidone palmitate) Receives the US FDA's Approval for the Treatment of Schizophrenia

Shots:

  • The approval is based on a P-III study that evaluates Invega hafyera (q6mos.- twice-yearly injectable) vs Invega trinza in 702 adults in a ratio (2:1) aged 18-70yrs. with schizophrenia from 20 countries
  • The results showed non-inferiority on 1EPs of time to 1st relapse @12mos. in ITT & per-protocol analysis sets.- patients were relapse-free (92.5% vs 95%) @12mos. & safety profile was consistent with previous studies with no new safety signals were observed
  • Additionally- patients who take Invega Hayfera must first be treated with Invega Sustenna for 4mos. or Invega Trinza for 1mos. injection cycle. Janssen’s CarePath provides a comprehensive support program to help patients on Invega hafyera

Ref: PR Newswire | Image: Janssen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions